Introduction: The Evolution of Incretin-Based Therapies
The landscape of metabolic medicine has been fundamentally altered by the advent of incretin mimetics. While glucagon-like peptide-1 receptor (GLP-1R) agonists have long been the cornerstone of treatment for type 2 diabetes (T2D) and obesity, the recent success of dual and triple agonists—most notably the GIP/GLP-1 receptor agonist tirzepatide—has sparked intense scientific inquiry into the specific contributions of the glucose-dependent insulinotropic polypeptide (GIP) component. Historically, GIP was viewed with skepticism due to its attenuated insulinotropic effect in patients with T2D. However, emerging evidence suggests that GIP agonism may synergize with GLP-1 to enhance weight loss and glycemic control while potentially mitigating gastrointestinal side effects.
A pivotal new study published in Molecular Metabolism investigates LY3537021, a novel, long-acting GIP receptor (GIPR) agonist. This research provides a critical look at the effects of GIPR agonism in isolation, offering insights into its independent therapeutic potential and its role within the broader context of multi-agonist therapies.
